Background: There is ongoing debate about nonpalliative primary tumor surgery in metastatic breast cancer patients. This issue has become even more relevant with the introduction of increasingly sensitive imaging modalities. Methods: Metastatic breast cancer patients were identified in the SEER registry between 1998 and 2009. The effect of primary tumor surgery on overall and cancer-specific mortality using risk-adjusted Cox proportional hazard regression modeling and stratified propensity score matching was assessed. Results: Overall, 16,247 women with metastatic breast cancer were included. Of those 7600 women underwent primary tumor surgery although 8647 did not have any surgery at all. Primary tumor surgery decreased from 62.0% in 1998 to 39.1% in 2009 (P < 0.001). Primary tumor surgery was associated with decreased overall mortality (hazard ratio (HR) ¼ 0.53, 95% CI 0.50-0.55, P < 0.001) and cancer-specific mortality (HR ¼ 0.51, 95% CI 0.48-0.54, P < 0.001) in the propensity score-matched model. The benefit of primary tumor surgery increased from 1998 to 2009 for overall mortality Conclusions: The present study-the first population-based analysis using propensity score methods-provides evidence of a favorable impact of primary tumor surgery on mortality in metastatic breast cancer patients. Most importantly, the benefit of primary tumor surgery increased over time from 1998 to 2009. Although the final results of ongoing randomized studies are awaited, currently available evidence should be discussed with metastatic breast cancer patients.
A ccording to the 2012 cancer statistics, breast cancer is the second most common cause for cancer deaths in the US. 1 Approximately 232,340 new cases of invasive breast cancer and 39,620 breast cancer deaths are expected to occur among US women in 2013.
Hence, 1 in 8 women in the US will develop breast cancer in her lifetime.
2 Approximately 5% to 10% of patients present with distant metastases at diagnosis; still, one-fifth of these patients will survive 5 years. 3 Primary tumor surgery for patients with metastatic breast cancer at diagnosis should be considered in case of impending local complications such as ulceration or fungation (''palliative surgery''), but is not recommended otherwise (''nonpalliative surgery'') in the US by the National Comprehensive Cancer Network. 4 According to European guidelines, local surgery may be considered in case of limited metastatic presentation and provided systemic tumor is well controlled. 3 However, the patterns of metastatic breast cancer has undergone some changes with increasingly sensitive imaging modalities, resulting in potential stage migration. This allows clinicians to even better identify metastatic breast cancer patients with an improved prognosis and the potential to benefit from a more aggressive local or systemic treatment approach.
Despite the prevailing, clear recommendation against nonpalliative primary tumor surgery in metastatic breast cancer, removing the primary tumor has been associated with decreased overall mortality in several retrospective studies, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] with a hazard ratio for mortality of 0.65 (0.59-0.72) 19 and 0.69 (0.63-0.77) 20 according to 2 recent meta-analyses. These results were found after multivariable statistical adjustment for confounding factors such as patient age, oligo-/multimetastatic status, hormone and HER2 receptor status, nodal status, and adjuvant local and systemic treatment among others. However, all studies are retrospective in nature, and potentially suffer from case selection bias, with better prognosis patients being more likely to undergo primary tumor surgery. This selection bias cannot definitely be precluded by usual multivariable adjustment, and may thus contribute to the survival advantage found in patients undergoing primary tumor surgery. 21 The objective of this study was to assess the prognostic value of primary tumor surgery in metastatic breast cancer patients, and to analyze mortality trends associated with primary tumor surgery over a 12-year time period after minimizing a potential case selection bias by implementing stratified propensity score-matching.
METHODS

Database and Cohort Definition
The recent ASCII text data-version of the Surveillance, Epidemiology and End Results (SEER) Program of the US National Cancer Institute (NCI) was used as the data source for the present population-based investigation. The SEER program is a populationbased cancer registry covering approximately 26% of the US population across several geographic regions, and is the largest publicly available cancer dataset. The SEER Registry collects stage at diagnosis, age at diagnosis, cancer type, gender, and race. SEER data were collected and reported using data items and codes as documented by the North American Association of Central Cancer From the Registries (NAACCR). 22 Primary cancer site and histology were coded according to the third edition of the International Classification of Diseases for Oncology (ICD-O-3). 23 Breast cancer was selected by using the ICD-O-3 codes C500 to C506, 508 or 509 and the behavior items 522 and 523 according to the NAACCR. 22 We excluded cases only diagnosed at autopsy, and death-certificated cases without histopathological confirmation. The analysis was restricted to ductal, lobular or mixed ductal and lobular carcinoma, according to the ICD-O-3 histology codes 8500 to 8543 (NAACCR Item 522). We excluded patients with secondary malignancies at the time of breast cancer diagnosis (NAACCR Item 380), patients with breast cancer other than stage IV (NAACCR Items 790 and 2980), patients who underwent surgery of distant metastases (NAACCR Items 1294 and 1648), or patients who lacked adequate information on primary tumor surgery (NAACCR Items 1290 and 1646). Of 601,801 adult (!18 years of age) women with a diagnosis of breast cancer between the years 1998 and 2009 included into the SEER Registry, 16,247 women were eligible for inclusion into the present study ( Figure 1, consort diagram) . Eligible patients were grouped according to whether or not they had undergone primary tumor surgery, including partial and subcutaneous mastectomy (NAACCR Items 1290 and 1646). The primary analysis was carried out in the intention-to-treat population (N ¼ 16,247), with the few patients who died before the intended primary tumor surgery (N ¼ 29) being allocated to the surgery group (NAACCR Item 1340).
Statistical Analysis
Statistical analysis was carried out using the R statistical software (www.r-project.org). Patient and treatment characteristics were described using summary statistics, with continuous variables being expressed as mean AE standard deviation. P-values for comparing proportions and continuous variables were calculated using x 2 statistics and t tests, respectively. Temporal trends for primary tumor surgery were analyzed using Spearman's rank correlation. Cox proportional hazard models were used to compare overall mortality between the surgical and nonsurgical groups. P-values based on likelihood ratio tests were used to compare patient mortality. The proportional hazard assumption was tested by scaled Schoenfeld Surgery in Metastatic Breast Cancer residuals and by inspection of the hazard ratio (HR) plots. 24 Primary tumor surgery was tested as a prognostic factor for mortality in uniand multivariable Cox regression analysis. Multivariable analysis was adjusted for year of initial breast cancer diagnosis, patient age, ethnicity, marital status, place of birth, location of the primary tumor, estrogen receptor (ER)-and progesterone receptor (PR)-status, regional lymph node status (dichotomized), histological grading and local radiotherapy. To further adjust for potential baseline confounders, a propensity score matching was carried out as described previously [25] [26] [27] with stratification for the year of diagnosis using the ''MatchIt'' and the ''optmatch'' R packages. 28 In the matching procedure, a certain patient could have multiple counterparts in the other group (''bipartite'') and its weight in the analysis could be down-or upweighted resulting in decimals for numbers of patients. 28 Patients with primary tumor surgery not having a counterpart with similar characteristics among the patients who did not undergo primary tumor surgery and vice versa were excluded from this part of analysis. Afterwards, the baseline risk profiles of the matched patients were compared with assurance that no major difference in baseline characteristics remained for the main analysis. The prognostic value of primary tumor surgery for mortality was assessed in a Cox regression analysis based on the aforementioned propensity score matching. Patients who died before a planned surgery was carried out were accounted in the surgery group according to the intention-to-treat principal. Subsequently, the entire analysis was repeated after substituting unknown or undocumented data using random survival forest methodology for sensitivity analysis. 29 All tests were 2-sided, and a P value of less than 0.05 was considered statistically significant.
RESULTS
Patient Characteristics and Treatment Trend
Of the 16,247 women included in the study (Figure 1 ), 7600 stage IV breast cancer patients underwent primary tumor surgery as defined above (surgery group), whereas 8647 women did not (nonsurgery group). The following surgical procedures were carried out: modified radical mastectomy (N ¼ 3527, 21.7%), partial mastectomy (N ¼ 2826, 17.4%), total mastectomy (N ¼ 1036, 6.4%), radical mastectomy without further specification (N ¼ 92, 0.6%), mastectomy without further specification (N ¼ 71, 0.4%), extended radical mastectomy (N ¼ 15, 0.1%), and subcutaneous mastectomy (N ¼ 4, 0.02%). In 29 patients (0.2%), surgery was planned but the patient died before surgery. Treatment characteristics across groups are outlined in Table 1 , showing a significant decrease of primary tumor surgery over time, more surgery in hormone receptor-positive and in nodal-positive breast cancer. The overall proportion of stage IV breast cancer in the extracted SEER population was 3.8%, with a moderate increase over time (from 3.1% in 1998 to 4.4% in 2009, P < 0.001) ( Figure 2 ). Primary tumor surgery in metastatic breast cancer patients decreased from 62.0% in 1998 to 39.1% in 2009 (P < 0.001), with similar patterns in patients equal to or less than 65 years (63.2% in 1998 to 42.0% in 2009, P < 0.001) and patients above 65 years (60.6% in 1998 to 34.5% in 2009, P < 0.001).
Primary Tumor Surgery and Clinical Outcome
The prognostic impact of primary tumor surgery on overall cancer-specific mortality is outlined in Figure 3 . Kaplan-Meier curves show lower overall mortality in patients undergoing primary tumor surgery compared with patients not undergoing primary tumor surgery ( Figure 3A) . Similar results can be seen for cancer-specific mortality ( Figure 3B ). Overall mortality decreased for patients with a more recent diagnosis of stage IV breast cancer, both in the surgery (P < 0.001) and in the nonsurgery groups (P < 0.001). Median overall and cancer-specific survival are shown in Figure 3C ,D, respectively. The hazard ratios for overall and cancer-specific mortality decreased over consecutive years ( Figure 3E ,F). Primary tumor surgery remained a significant prognostic factor in the adjusted Cox regression model for overall mortality (Hazard Ratio for death ¼ 0.60, 95% CI ¼ 0.58 to 0.63, P < 0.001) and for cancerspecific mortality (HR ¼ 0.59, 95% CI ¼ 0.56 to 0.61, P < 0.001) ( Table 2) .
Adjusting for Patient Characteristics Using Propensity Score Matching
To account for potential bias due to an imbalance between the surgery and nonsurgery groups regarding the year of first diagnosis, patient age, ethnicity, socio-cultural characteristics, tumor location, grading, location and postoperative radiotherapy, and propensity score matching with stratification for the year of diagnosis was carried out as described above. The propensity for patients in the surgery group was 0.56 (AE0.17) compared with 0.39 (AE0.19) for patients in the nonsurgery group (P < 0.001). After the matching procedure, the propensity score improved to near equality (0.55 AE 0.17 for both groups, P < 0.001). Propensity score matching procedure resulted in the exclusion of 224 patients (75 patients in the surgery group, 149 in the nonsurgery group, 1.4% overall) who lacked a propensity score match. Figure 4 displays the distribution of the propensity scores of the 2 patient groups before and after propensity score matching procedure. By propensity score matching, imbalance across the 2 patient groups could be avoided for most parameters, except hormone receptor and nodal status (Table 1) . Propensity score matching accounted for remaining imbalances within patient groups regarding the year of diagnosis. In the Cox regression model after propensity score matching, primary tumor surgery remained a prognostic factor for overall mortality (HR ¼ 0.53, 95% CI ¼ 0.50 to 0.55, P < 0.001) and cancer-specific mortality (HR ¼ 0.51, 95% CI ¼ 0.48 to 0.54, P < 0.001) ( Table 2 ).
Sensitivity Analysis
Imputation of missing data by a random survival forest method did not affect overall study results. After data imputation and multivariable adjustment, primary tumor surgery remained a prognostic factor for overall mortality (HR ¼ 0.57, 95% CI ¼ 0.55-0.59, P < 0.001) and cancer-specific mortality (HR ¼ 0.56, 95% CI ¼ 0.54-0.58, P < 0.001).
DISCUSSION
The present study is the first population-based analysis using propensity score matching to assess the impact of primary tumor surgery in metastatic breast cancer patients. Our investigation provides evidence of a clear association of primary tumor surgery in stage IV patients with decreased overall and cancer-specific mortality in a large patient cohort. Both Cox proportional hazard regression and analyses after propensity score matching demonstrate a benefit of primary tumor removal regardless of the investigated patient and treatment characteristics. Most importantly, the hazard ratio for overall and cancer-specific mortality decreased from 1998 to 2009, suggesting an increasing benefit of primary tumor surgery over the study period. Similar to our investigation, several uncontrolled retrospective studies [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] and 2 meta-analyses 20, 30 found primary tumor surgery to have a favorable prognostic impact in stage IV breast cancer patients. In the first meta-analysis based on data from 15 studies, Petrelli et al found a hazard ratio of 0.69 (95% CI 0.63-0.77) for overall mortality in patients undergoing primary tumor surgery. 20 The second meta-analysis of Harris et al including 28,693 patients from 10 clinical studies reported a significantly decreased overall mortality at 3 years in patients undergoing primary tumor zTwo hundred and twenty-four patients were excluded in the propensity score matching procedure. §Includes 34 patients with unknown ethnicity. ôThirty-nine patients with borderline estrogen receptor status.
Warschkow et al
jjOne hundred and twenty-five patients with borderline progesterone receptor status. Hazard ratios (HR) with 95% confidence intervals.
surgery versus those not undergoing primary tumor surgery (40% vs 22%, P < 0.01). The data from Neuman et al suggested that the survival benefit from primary tumor surgery is most relevant in patients with ER-positive or HER2-positive disease, 12 potentially resulting from decreased mortality due to effective systemic treatment in these patient subgroups. The present analysis found a significant trend toward decreased overall and cancer-specific mortality over the studied period, irrespective of primary tumor surgery. A similar trend for improved survival has already been described in 2004 by Andre et al, adding up to a significant 3-year overall survival improvement from 27% in 1994 to 44% in 2000 in stage IV breast cancer patients. 31 It is unclear whether there were concurrent treatment trends responsible for the improved prognosis over time, because SEER Registry data do not provide information on systemic treatments such as chemotherapy, endocrine, or anti-HER2-targeted agents. Stage migration due to more frequently used sensitive imaging such as PET-CT may have contributed in part to the observed trend of improved prognosis over time.
Interestingly, the survival benefit in the primary surgery group increased over time in the present study, in parallel with a decreased proportion of patients with metastatic breast cancer undergoing primary tumor surgery. Although a potential causal relationship between primary tumor surgery and decreased mortality in stage IV breast cancer patients can only definitively be clarified in prospective randomized studies, the present data suggest an unfavorable trend in the selection of metastatic breast cancer patients for primary tumor surgery. This may partly be a consequence of the improved overall prognosis of patients with metastatic breast cancer, 31 or some stage migration resulting in more patients being diagnosed with oligometastatic, more indolent disease, for example by increasing use of PET-CT. The decrease in primary tumor surgery may partially be explained by increasingly sensitive imaging modalities during the study period causing a shift to a higher fraction of metastatic patients with a lower tumor burden on average. Patients in later years are then less likely to undergo surgery of the primary.
Between 5% and 10% of patients with stage IV disease survive 5 or more years, and 2%-5% become long-term survivors. 32, 33 In these patients, combined modality approaches, including primary tumor surgery, are suggested to improve clinical outcomes over systemic treatment alone. This parallels data from other solid malignancies such as renal-cell, 34 ovarian, 35 or colorectal cancer 36 among others, for which a reduction of tumor burden has been reported to be a favorable prognostic factor. Moreover, recent research on circulating tumor cells further supports a maximum tumor debulking, showing a strong correlation between tumor volume and circulating tumor cells, and between circulating tumor cells and the prognosis in metastatic breast cancer patients. [37] [38] [39] Despite the attractiveness of removing the primary tumor as a potential source of further tumor spread 40 or as a cause for immune suppression, the effect of tumor-specific biology, including growth kinetics, route of metastatic spread, and responsiveness to systemic therapies, differ widely among patients and tumor types, and make any general evaluation futile. On the contrary, there are also preclinical data suggesting that an intact primary tumor may suppress the growth of distant metastases. 41 Eventually, the results of the 5 currently ongoing randomized, controlled trials (in the US, India, Austria, The Netherlands, and Turkey) addressing the role of primary tumor surgery in patients with metastatic breast cancer will have to be awaited before being able to make definite conclusions. Preliminary results of the Turkish and Indian studies have been reported at the 2013 San Antonio Breast Cancer Symposium. Although in the Turkish MF07-01 trial median overall survival was improved by a nonsignificant 4 months (from 46 months in the surgery group and 42 months in the group receiving systemic treatment only), overall survival was 18 months in both groups in the Indian study. 42, 43 As a note of caution, the Indian study included only patients responding to anthracycline or taxane chemotherapy, and 10% in the no-surgery arm received palliative surgery of the primary tumor. Moreover, a median overall survival of 18 months is low. It is thus questionable whether these results can be extrapolated to the patient population in western countries.
We would like to acknowledge the limitations of the present study. Given the limited resolution of the SEER Registry, a bias due to the imbalance of the surgery compared with the nonsurgery group cannot be excluded. However, both multivariable analysis and additional propensity score matching were carried out to reduce potential confounding. Furthermore, only known prognostic factors can be included in multivariable analysis, although unidentified FIGURE 2. Trend for metastatic disease and its treatment. prognostic factors such as type of axillary surgery, performance status, volume and location of the metastases, sequence of diagnosis of primary tumor and metastases, and type of radiation therapy were not adjusted for and may have contributed to the observed results. Additionally, the SEER Registry does not provide any data on systemic treatment in these patients, making any adjustment impossible for the use of chemotherapy, endocrine or anti-HER2 targeted treatment. Nonetheless, it seems unlikely that the large beneficial effects of primary tumor surgery are due solely to unadjusted confounding. The investigation of registry data-although by nature retrospective-is one of the strengths of our study. Registry data have usually high completeness and are representing the entire patient population, whereas prospective randomized trials are prone to a selection bias by entering good performance and oligometastatic patients possibly benefitting most from primary surgery in such trials.
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In conclusion, the present study supports the favorable impact of primary tumor surgery on clinical outcomes in patients with metastatic breast cancer at initial diagnosis. Most importantly, the benefit of primary tumor surgery increased over time between 1998 and 2009. Although further results of ongoing randomized studies are awaited, currently available evidence should be discussed with patients.
